Chronic Hepatitis B Virus
Conditions
Brief summary
The objective of this study was to evaluate the efficacy and safety of TVAX-008 Injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial in NAs-treated subjects with chronic hepatitis B. 80 subjects are planned to be enrolled in this study and divided into 2 groups. After a screening period of no more than 4 weeks, eligible subjects will be randomly assigned to enter the double-blind treatment period according to the ratio of 1:1, and receive TVAX-008 injection or placebo in combination with NAs for 24 weeks. At the end of the double-blind treatment period, subjects with HBsAg negative and HBsAg\>100 mIU/mL continued to be followed up to Week 73; subjects with HBsAg not negative or HBsAg negative but HBsAg ≤100 mIU/mL entered the open-label treatment period and received TVAX-008 injection combined with NAs for 24 weeks, and continued to be followed up for 24 weeks after the end of the open-label treatment period.
Interventions
DRUGTVAX-008
TVAX-008
DRUGPlacebo
Placebo
Sponsors
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Voluntary signing of the informed consent form, understanding of the study and willingness to follow and ability to complete all trial procedures; 2. Male or female, age 18-65 (including thresholds) 3. Clinically diagnosed chronic hepatitis B (HBsAg positive serum ≥6 months) 4. Subjects receiving antiviral therapy with a single nucleotide analogue such as tenofovir fumarate (TAF), tenofovir amitidine (TMF), tenofovir disotil fumarate (TDF), or entecavir (ETV) and HBV DNA\<100 IU/mL within 28 days prior to first dose of investigational product 5. HBeAg negative within 28 days prior to first use of investigational product 6. HBsAg\>0.05 IU/mL and HBsAg\<100 IU/mL within 28 days prior to first use of investigational product
Exclusion criteria
1. Clinically important chronic diseases other than chronic hepatitis B that, in the opinion of the investigator, make the patient unsuitable for participation in the study 2. Laboratory indicators or symptoms meet one or more of the following: 1) blood phosphorus \<0.65 mmol/L; 2) serum albumin \<35 g/L; 3) total bilirubin\> 1.5 × ULN; 4) hemoglobin \<90 g/L; 5) international normalized ratio of prothrombin time ≥ 1.5; 6) ascites, varicose vein bleeding, hepatorenal syndrome, hepatic encephalopathy or liver failure; 7) platelet count \<90 × 109/L; INR 8) absolute neutrophil count \<1.2 × 109/L; 9) serum creatinine\> 1.5 × ULN or creatinine clearance \<50 mL/min/1.73m2; imaging findings showing cirrhosis or liver space-occupying lesions (except liver cysts or hemangiomas) 3. Treatment with interferon or pegylated interferon within 12 weeks prior to first use of investigational product or planned treatment with interferon or pegylated interferon during the trial 4. Use of immunosuppressants within 6 months prior to first use of investigational product 5. Treatment with corticosteroids (other than topical or inhaled corticosteroids) for 1 week or more within 6 months prior to first use of investigational product
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HBsAg negative conversion rate | week37 | HBsAg negative conversion rate |
Countries
China
Outcome results
None listed